Phase II study of E7389 [eribulin], a halichondrin B analog, in patients with advanced non-small cell lung cancer (NSCLC), who progressed during or after platinum-based doublet chemotherapy stratified for prior taxane therapy.

Trial Profile

Phase II study of E7389 [eribulin], a halichondrin B analog, in patients with advanced non-small cell lung cancer (NSCLC), who progressed during or after platinum-based doublet chemotherapy stratified for prior taxane therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2012

At a glance

  • Drugs Eribulin (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Oct 2009 Actual patient number (106) added as reported by ClinicalTrials.gov.
    • 19 Aug 2008 Planned end date (Dec 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top